Phosphodiesterase 3 inhibition reduces platelet activation and monocyte tissue factor expression in knee arthroplasty patients

Anesthesiology

Volumn 111, Issue 6, 2009, Pages 1227-1237

  Beppu, Satoru ^a   Nakajima, Yasufumi ^a   Shibasaki, Masayuki ^a   Kageyama, Kyoko ^a   Mizobe, Toshiki ^a   Shime, Nobuaki ^a   Matsuda, Naoyuki ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; DUAL SPECIFICITY PHOSPHATASE 2; FIBRIN MONOMER; INTEGRIN; INTEGRIN ALPHA2B BETA3; MILRINONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE TISSUE FACTOR; PADGEM PROTEIN; PHOSPHODIESTERASE III; PROTEIN KINASE B; SODIUM CHLORIDE; THROMBOPLASTIN; UNCLASSIFIED DRUG; FIBRIN DEGRADATION PRODUCT; FIBRINMONOMER; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE INHIBITOR;

ADULT; AGED; ARTICLE; ATTENUATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME PHOSPHORYLATION; FEMALE; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE AGGREGATION; LEUKOCYTE FUNCTION; MALE; MONOCYTE; OSTEOARTHRITIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TOTAL KNEE REPLACEMENT; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING; DRUG ANTAGONISM; FLOW CYTOMETRY; GENERAL ANESTHESIA; KNEE ARTHROPLASTY; METABOLISM; MIDDLE AGED; THROMBOCYTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; ANESTHESIA, GENERAL; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD COAGULATION; BLOOD PLATELETS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MILRINONE; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; ONCOGENE PROTEIN V-AKT; P-SELECTIN; PHOSPHODIESTERASE INHIBITORS; PLATELET ACTIVATION; PROSPECTIVE STUDIES; THROMBOPLASTIN;

EID: 73449140448     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181c155ce     Document Type: Article

References (41)

1. Rosenfeld BA, Faraday N, Campbell D, Dise K, Bell W, Goldschmidt P: Hemostatic effects of stress hormone infusion. ANESTHESIOLOGY 1994; 81:1116-1126
2. Rosenfeld BA, Nguyen ND, Sung I, Faraday N: Neuroendocrine stress hormones do not recreate the postoperative hypercoagulable state. Anesth Analg 1998; 86:640-645
3. Mizobe T: Haematological effects of anaesthetics and anaesthesia. Curr Opin Anaesthesiol 1999; 12:437-441
4. Samama CM, Thiry D, Elalamy I, Diaby M, Guillosson JJ, Kieffer E, Coriat P: Perioperative activation of hemostasis in vascular surgery patients. ANESTHESIOLOGY 2001; 94:74-78
5. Kageyama K, Nakajima Y, Shibasaki M, Hashimoto S, Mizobe T: Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty. J Thromb Haemost 2007; 5:738-745
6. Furman MI, Frelinger AL III, Michelson AD: GPIIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis 2004; 18:11-17
7. Michelson AD, Furman MI: Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999; 6:342-348
8. Furie B, Furie BC: Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10:171-178
9. Polgar J, Matuskova J, Wagner DD: The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005; 3:1590-1596
10. Adam F, Kauskot A, Rosa JP, Bryckaert M: Mitogen-activated protein kinases in hemostasis and thrombosis. J Thromb Haemost 2008; 6:2007-2016
11. Hankey GJ, Norman PE, Eikelboom JW: Medical treatment of peripheral arterial disease. JAMA 2006; 295:547-553
12. Matsumoto M: Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005; 6:33-40
13. Barradas MA, Jagroop A, O'Donoghue S, Jeremy JY, Mikhailidis DP: Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: An in vitro study. Thromb Res 1993; 71:227-236
14. Cone J, Wang S, Tandon N, Fong M, Sun B, Sakurai K, Yoshitake M, Kambayashi J, Liu Y: Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999; 34:497-504
15. Kikura M, Lee MK, Safon RA, Bailey JM, Levy JH: The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg 1995; 81:44-48
16. Kikura M, Sato S: Effects of preemptive therapy with milrinone or amri-none on perioperative platelet function and haemostasis in patients undergoing coronary bypass grafting. Platelets 2003; 14:277-282
17. Seino Y, Momomura S, Takano T, Hayakawa H, Katoh K: Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. Crit Care Med 1996; 24: 1490-1497
18. Kumar SN, Chapman JA, Rawlins I: Vascular injuries in total knee arthro-plasty: A review of the problem with special reference to the possible effects of the tourniquet. J Arthroplasty 1998; 13:211-216
19. Kohro S, Yamakage M, Arakawa J, Kotaki M, Omote T, Namiki A: Surgical/ tourniquet pain accelerates blood coagulability but not fibrinolysis. Br J Anaesth 1998; 80:460-463
20. Hughes SF, Hendricks BD, Edwards DR, Bastawrous SS, Roberts GE, Middleton JF: Mild episodes of tourniquet-induced forearm ischaemia-reperfusion injury results in leukocyte activation and changes in inflammatory and coagulation markers. J Inflamm (Lond) 2007; 4:12
21. Hiramatsu N, Kageyama K: Anti-thrombotic effect of milrinone is caused by inhibition of calcium release from the dense tubular system in human platelets. Acta Anaesthesiol Scand 2003; 47:53-57
22. Tamai Y, Takami H, Nakahata R, Ono F, Munakata A: Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 1999; 29:269-276
23. Suzuki K, Sakai Y, Hisamichi N, Taniuchi Y, Sato K, Terazaki C, Kaku S, Kawasaki T, Yano S, Inagaki O, Masuho Y: Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. Eur J Pharmacol 1997; 336:169-176
24. Singh J, Zeller W, Zhou N, Hategen G, Mishra R, Polozov A, Yu P, Onua E, Zhang J, Zembower D, Kiselyov A, Ramirez JL, Sigthorsson G, Bjornsson JM, Thorsteinsdottir M, Andresson T, Bjarnadottir M, Magnusson O, Fabre JE, Stefans-son K, Gurney ME: Antagonists of the EP(3) receptor for prostaglandin E(2) are novel antiplatelet agents that do not prolong bleeding [published on-line ahead of print February 5, 2009]. ACS Chem Biol
25. Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H: A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004; 11:600-602
26. Li H, Cone J, Fong M, Kambayashi J, Yoshitake M, Liu Y: Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation. Cardiovasc Drugs Ther 2005; 19: 41-48
27. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003; 9:2289-2302
28. Onoda K, Ohashi K, Hashimoto A, Okuda M, Shimono T, Nishikawa M, Shimpo H: Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. Ann Thorac Car-diovasc Surg 2008; 14:230-237
29. Goto S: Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6:3-11
30. Tsai CS, Lin FY, Chen YH, Yang TL, Wang HJ, Huang GS, Lin CY, Tsai YT, Lin SJ, Li CY: Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated mono-cytic THP-1 cells. J Cell Biochem 2008; 103:54-66
31. Furie B, Furie BC: In vivo thrombus formation. J Thromb Haemost 2007; 5 (suppl 1):12-17
32. Kamikura Y, Wada H, Nobori T, Kobayashi T, Sase T, Nishikawa M, Ishikura K, Yamada N, Abe Y, Nishioka J, Nakano T, Shiku H: Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 2005; 116:307-312
33. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG: The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004; 2:561-573
34. Begonja AJ, Geiger J, Rukoyatkina N, Rauchfuss S, Gambaryan S, Walter U: Thrombin stimulation of p38 MAP kinase in human platelets is mediated by ADP and thromboxane A2 and inhibited by cGMP/cGMP-dependent protein kinase. Blood 2007; 109:616-618
35. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X: Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 2009; 113:893-901
36. Garcia A, Quinton TM, Dorsam RT, Kunapuli SP: Src family kinase-medi-ated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood 2005; 106: 3410-3414
37. Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP: P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006; 4:638-647
38. Jackson SP, Yap CL, Anderson KE: Phosphoinositide 3-kinases and the regulation of platelet function. Biochem Soc Trans 2004; 32:387-392
39. Resendiz JC, Kroll MH, Lassila R: Protease-activated receptor-induced Akt activation-regulation and possible function. J Thromb Haemost 2007; 5:2484-2493
40. Golino P, Ragni M, Cirillo P, Avvedimento VE, Feliciello A, Esposito N, Scognamiglio A, Trimarco B, Iaccarino G, Condorelli M, Chiariello M, Ambrosio G: Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 1996; 2:35-40
41. Vilahur G, Hernandez-Vera R, Molins B, Casani L, Duran X, Padro T, Badimon L: Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells. J Thromb Haemost 2009; 7:485-493